Last updated: February 24, 2026
What is NDC 70677-1266?
NDC 70677-1266 is the National Drug Code for Rituximab (Herceptin), a monoclonal antibody used primarily for HER2-positive breast cancer, non-Hodgkin’s lymphoma, and other autoimmune diseases.
Market Overview
Market Size and Growth
The global oncology drug market, which includes Rituximab, was valued at approximately $180 billion in 2021. It is projected to grow at a compound annual growth rate (CAGR) of approximately 7% through 2028, driven by rising cancer prevalence, aging populations, and expanding indications.
Key Players and Competition
- Genentech (Roche): Manufacturer of the branded product Herceptin.
- Mitsubishi Tanabe Pharma: biosimilars approved in select markets.
- Celltrion, Sandoz, Pfizer: Other biosimilar entrants.
Biosimilar Entry
Generic and biosimilar versions of Rituximab have increased market competition. In the US, biosimilars such as Truxima (celltrion) are approved, with market penetration intensifying since 2019.
Regulatory Landscape
- FDA approvals for biosimilars began in 2018.
- US patent protections for Herceptin expired in 2019, prompting biosimilar entries.
- The European Medicines Agency (EMA) approved biosimilars in 2017, leading to price discounts.
Price Analysis
Current List Prices
- Branded Herceptin (US, 2023): Approximately $6,000 – $8,000 per 440 mg vial.
- Biosimilars (US, 2023): Range from $4,800 to $6,000 per vial.
Price Trends
| Year |
Branded Price Range (per vial) |
Biosimilar Price Range (per vial) |
| 2018 |
$7,100 – $8,000 |
N/A |
| 2020 |
$6,500 – $7,500 |
$4,800 – $6,000 |
| 2023 |
$6,000 – $8,000 |
$4,800 – $6,000 |
Factors Affecting Price
- Increased biosimilar competition reduces prices.
- Payer pressure influences discounts and formulary placement.
- Market penetration varies by region; US and Europe exhibit different dynamics.
Future Price Projections
- Biosimilar prices are expected to decrease by an additional 10-20% over the next 2 years.
- Branded Herceptin may maintain a premium, though it could face pressure from biosimilar entries.
| Projection Year |
Branded Price (per vial) |
Biosimilar Price (per vial) |
| 2024 |
$5,800 – $8,200 |
$4,300 – $5,800 |
| 2025 |
$5,600 – $7,800 |
$4,000 – $5,200 |
Market Drivers and Risks
Drivers
- Rising cancer incidence globally.
- Expanded indications for Rituximab (autoimmune diseases, new oncology uses).
- Increased biosimilar adoption.
Risks
- Regulatory delays or restrictions on biosimilar interchangeability.
- Patent litigation delaying biosimilar market entry.
- Price controls from government agencies.
Key Takeaways
- The Rituximab market, dominated by branded Herceptin, faces increasing competition from biosimilars.
- US prices for biosimilars are currently 25-30% lower than branded prices.
- Price declines for biosimilars are expected to accelerate over the next two years.
- Market growth is driven by expanding indications and rising cancer rates, especially in aging populations.
- Price sensitivity varies across regions; US market prices are influenced heavily by payer negotiations, while Europe has more aggressive biosimilar adoption.
FAQs
What is the primary therapeutic use of NDC 70677-1266?
Rituximab is used mainly to treat HER2-positive breast cancer, non-Hodgkin’s lymphoma, and some autoimmune diseases like rheumatoid arthritis.
How competitive is the Rituximab market?
The market features significant competition due to biosimilars, with several approved in the US and Europe since 2017-2018.
What are the expected price trends for Rituximab biosimilars?
Biosimilar prices are anticipated to decline by 10-20% over the next two years, driven by increased competition and market penetration.
How do regional differences impact Rituximab pricing?
The US exhibits higher prices with more payer negotiations, while Europe has seen faster biosimilar adoption and lower prices.
What factors could impact future Rituximab prices?
Regulatory decisions, patent litigation, biosimilar market acceptance, and healthcare policy changes could influence prices.
References
- MarketWatch. (2022). Oncology drug market size and forecasts.
- IQVIA. (2022). Biosimilar landscape and pricing analysis.
- EMA. (2017). Biosimilar approvals and market entry.
- FDA. (2022). Biosimilar approvals and regulatory updates.
- CB Insights. (2023). Competitive dynamics in the biosimilar market.
This analysis is based on current publicly available data and market trends as of early 2023. Price projections are subject to change based on regulatory, market, and competitive developments.
